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Abstract
Several species of Gram-positive bacteria can avidly bind soluble and surface-associated fibrinogen (Fng), a property
that is considered important in the pathogenesis of human infections. To gain insights into the mechanism by which
group B Streptococcus (GBS), a frequent neonatal pathogen, interacts with Fng, we have screened two phage
displayed genomic GBS libraries. All of the Fng-binding phage clones contained inserts encoding fragments of FbsA,
a protein displaying multiple repeats. Since the functional role of this protein is only partially understood,
representative fragments were recombinantly expressed and analyzed for Fng binding affinity and ability to induce
immune protection against GBS infection. Maternal immunization with 6pGST, a fragment containing five repeats,
significantly protected mouse pups against lethal GBS challenge and these protective effects could be recapitulated
by administration of anti-6pGST serum from adult animals. Notably, a monoclonal antibody that was capable of
neutralizing Fng binding by 6pGST, but not a non-neutralizing antibody, could significantly protect pups against lethal
GBS challenge. These data suggest that FbsA-Fng interaction promotes GBS pathogenesis and that blocking such
interaction is a viable strategy to prevent or treat GBS infections.
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Introduction
The Gram positive bacterium Streptococcus agalactiae
(group B Streptococcus, GBS) is a frequent colonizer of the
intestinal and genital tracts of humans and a leading neonatal
pathogen [1,2]. Maternal colonization with GBS is the primary
risk factor for life-threatening neonatal infections, including
pneumonia, sepsis and meningitis. Moreover, GBS frequently
causes arthritis, endocarditis and sepsis in adults with
underlying chronic disease and in elderly people [3]. The
pathogenic potential of these bacteria is dependent on the
expression of a large variety of surface-exposed virulence
factors [4]. Colonization and invasion of host barriers is, at least
partially, related to the ability of GBS to bind human fibrinogen
(Fng) [5,6,7] and strains causing severe invasive infections can
strongly interact with this protein [8]. Fng is present at high
concentrations in plasma and in the extracellular matrix and
binds to host cells via a number of signaling and non-signaling
receptors [9]. Therefore, Fng can act as a molecular nexus
between pathogens and human tissues and can modulate a
number of host cell functions, particularly those involved in
inflammatory responses and coagulation [10].
The ability to bind Fng has been classically linked, in GBS, to
the expression of two surface proteins, FbsA and FbsB, with
their relative importance varying in strains belonging to different
clone types [11,12,13]. More recently, it was found that the Srr1
glycoprotein also contributes to Fng binding [14]. It is possible
that FbsA is sufficient for binding to epithelial and endothelial
cells, but not for cell invasion, a process for which FbsB [15] or
Srr1 [14] are also required. Moreover, FbsA mediates platelet
aggregation, which likely plays a role in GBS-induced
endocarditis [16]. Despite the potential importance of FbsA in
the pathogenesis of GBS disease, the mechanisms by which
this factor binds Fng and contributes to virulence are poorly
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understood. FbsA displays a variable number of tandem
repeats and a wall-anchoring region. Deletion of fbsA resulted
in decreased virulence in a murine model of septic arthritis [17].
However, neither active immunization with the N-terminal
portion of FbsA nor passive immunization with a neutralizing
anti-FbsA antibody had protective effects in that model [17],
suggesting a minor role, if any, of Fng binding in the virulence
properties of FbsA. In contrast, in a recent study, passive
immunization with polyclonal or monoclonal antibodies
protected mice against systemic GBS challenge [18]. Therefore
it is presently unclear whether FbsA can be a target for
immunization strategies to prevent GBS infection.
We describe here the isolation and functional properties of
FbsA protein fragments identified by screening genomic GBS
phage displayed libraries for the presence of Fng binding
clones. We found that maternal immunization with one of these
fragments conferred protection to offspring against lethal
challenge with GBS in a mouse model that closely mimics
human neonatal disease. Notably, immune protection in this
model was mediated by anti-FbsA antibodies and could be
recapitulated by administration of a monoclonal antibody that
was capable of neutralizing Fng binding, but not by a non-
neutralizing antibody. Our data suggest that blockade of FbsA-
mediated Fng binding may be a viable strategy in controlling
GBS disease and that FbsA fragments may be useful in the
development of a GBS vaccine.
Results
Selection of GBS display libraries
Two different phage display libraries were constructed using
partially digested genomic DNA from S. agalactiae strains
COH1 and 2603 V/R (serotypes III and V, respectively) and
affinity selected using Fng-coated magnetic beads. In a phage
ELISA assay, an increasing Fng binding of phage pools after
each selection round using the COH1, but not the 2603 V/R,
library was observed (Figure 1A). Consistent with this, no Fng-
binding clones were detected by plaque screening of the 2603
V/R library after selection, while 38 clones were isolated from
the COH1 library (Figure 1B). After these positive clones were
assayed by PCR, six different insert size groups were identified
and representative clones from each group (designated as 1p,
2p, 3p, 4p, 5p, and 6p) were selected for sequence analysis.
All of these sequences matched fbsA in the COH1 genome and
were predicted to encode protein fragments of the N-terminal
region of FbsA (Figure 1C). The complete sequences of these
inserts are reported in Table S1. Each of the fragments
contained one to five repeat units of an amino acid motif,
GNVLERRQRDA(V) E(D) NKSQ, implicated in Fng binding
[11]. In the 2603 V/R genome the fbsA locus (sag1052)
encodes a truncated protein that lacks the Fng-binding repeats,
perhaps explaining our inability to isolate Fng binding clones
from the 2603 V/R phage display library.
Fng binding activity of FbsA fragments
To analyze the ability of FbsA fragments to bind Fng, we
selected two phage clones, 5p and 6p, whose inserts encode
one and five repeats, respectively. As reported in Figure 2A,
when increasing particles from each clone were added to
surface-coated Fng, a saturable binding was observed, as
detected using anti-phage antibodies. This prompted us to
express 5p and 6p as recombinant proteins in fusion with GST.
In a competitive binding assay, both 5pGST and 6pGST
proteins efficiently inhibited binding of phages to immobilized
Fng (Figure 2, panels B and C). The direct binding of 5pGST
and 6pGST to Fng was also tested in an ELISA format. As
shown in Figure 3A, Fng bound to both surface-coated 5pGST
and 6pGST in a saturable manner, with half maximal binding
values of 31.2 ± 3 and 63 ± 3 nM, respectively. It was
previously established that the presence of an increasing
numbers of repeats in FbsA results in enhanced Fng binding
[11]. However, it is presently unclear whether this effect is
related to increased binding affinity or merely to the ability of
multiple repeats to bind multiple Fng molecules. To
Figure 1.  Selection and screening for Fng binding of
phage displayed genomic GBS libraries obtained from the
COH1 and the 2603 V/R strains.  A. Reactivity of GBS
libraries obtained after the indicated selection rounds. After
each selection round using Fng-coated beads, libraries were
tested for Fng binding using a phage ELISA assay (see
Materials and Methods). Columns and error bars represent
means + standard deviations of three replicate determinations.
B. Plaque immunoscreening of Fng-selected COH1 and 2603
V/R libraries showing individual Fng-binding clones as colored
dots. C. Schematic representation of FbsA fragments from
Fng-binding clones. Top to bottom: organization of the FbsA
protein encoded by the fbsA gene in the genome of GBS strain
COH1; predicted FbsA amino acid sequence; position of the
fragments (1p-6p) encoded by phage inserts along the FbsA
sequence. The horizontal axis represents amino-acid position.
Arrows indicate the predicted leader peptide (LP) cleavage site.
N-, N-terminal end; RD1-RD5, repeat domains 1-5; LPKTG,
cell wall anchoring motif; C-, C-terminal end.
doi: 10.1371/journal.pone.0075266.g001
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discriminate between these possibilities, the binding affinities of
5pGST and 6pGST to Fng were determined by SPR. To this
end, 5pGST or 6pGST were immobilized on a sensor chip,
over which different concentrations of Fng were subsequently
flowed. The results from equilibrium analysis revealed KD
values of Fng for 5pGST and 6pGST of 27.5 ± 4.7 and 23 ± 2.4
nM, respectively (Figure 3, panels B and C). These data
demonstrate that the one-repeat 5pGST and the five-repeat
6pGST FbsA fragments bound Fng with similar affinities,
suggesting that the presence of multiple repeats does not
result in increased affinity of FbsA-Fng interaction.
Active immunoprotection
So far, the effects of active immunization with FbsA have
been tested in one study only [17]. Thus, it was of interest to
explore the immunoprotective activity of our FbsA fragments in
different GBS sepsis models. To this end, the five-repeat
fragment (6pGST) was used to immunize adult mice and, after
three administrations, all mice had 6p-specific serum antibody
titers ranging from 1:8,000 to 1:64,000 (data not shown). Mice
were then challenged i.p. with 5 x 107 CFU of the COH1 strain
at 3 weeks after the last immunization and lethality was
observed for 14 days. Under these conditions, immunization
with 6pGST resulted in 77% (14 mice out of 18) survival, while
only 33% (6 mice out of 18) of the GST-immunized animals
survived (p< 0.01) (Figure 4A). In addition, blood colony counts
were significantly lower in 6pGST-immunized mice at 18 h after
challenge (Figure S1). Due to the inconsistence of our data
with those of the previous study cited above [17], we next
investigated whether 6pGST immunization could afford
protection against infection caused by the same GBS strain
(i.e. the 6313 strain) used in that study. Moreover, since the
goal of anti-GBS vaccination is to induce placentally
transferable antibodies, we ascertained whether maternal
6pGST immunization could protect mouse pups against GBS
challenge in a stringent model that closely mimics naturally
occurring neonatal infection [19]. Female mice were immunized
with 6pGST or GST as detailed above and time-mated. Their
offspring were then challenged with the 6313 strain at two days
of age. In a first experiment, 15 of 19 (79%) neonatal pups born
to dams vaccinated with 6pGST survived challenge with 100
CFU, compared with 43% of those born to GST-immunized
control mothers (p<0.05, data not shown). In a second
experiment (Figure 4B), 50% of neonatal pups born to dams
vaccinated with 6pGST survived GBS challenge, while all of
those born to GST-immunized control mothers died (p<0.05). In
each experiment, survival rates between litters within a test
group were similar (data not shown).
Passive immunoprotection
To clarify the mechanisms by which maternal 6pGST
immunization protected offspring from GBS infection, we first
ascertained whether protection could be induced by the
exogenous administration of immune sera. Serum samples
from 6pGST- or GST-immunized adult mice were pooled and
used to passively immunize two-day old pups. Each litter was
divided in 2 groups consisting of pups given either anti-6pGST
or anti-GST serum. In a first experiment, all pups receiving
anti-6pGST serum survived a challenge dose (100 CFU of the
6313 strain) that killed 56% of the anti-GST-treated animals
(p<0.05, data not shown). In an additional experiment, 62%
and 1% of, respectively, anti-6pGST and anti-GST-treated
pups survived infection (Figure 5A, p<0.05). The above-
described protective activities of anti-6pGST serum could be
related to a variety of antibody-dependent functions, including
bacterial opsono-phagocytic killing, neutralization of FbsA-
Figure 2.  Binding of Fng to phage particles in the presence and in the absence of inhibitors.  A. Binding to Fng of increasing
numbers of 5p or 6p lambda phage (λ5p or λ6p) particles. Plates were coated with Fng, and phage particles were added at the
indicated PFU numbers followed by anti-lambda phage rabbit IgG and alkaline phosphatase-labeled goat anti-rabbit IgG. Error bars
represent means ± standard deviations from three independent experiments; *, p<0.05 by analysis of variance followed by the
Student Newman Keuls test. B and C. Inhibition of binding of 5p or 6p lambda phage particles (λ5p or λ6p, 108 PFU) to immobilized
Fng in the presence of increasing concentrations of recombinant FbsA fragments (5pGST and 6pGST in panels B and C,
respectively) used as inhibitors. Data are from one experiment, representative of three producing similar results.
doi: 10.1371/journal.pone.0075266.g002
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Figure 3.  Interaction of Fng with recombinant FbsA
fragments.  A. Dose-dependent binding of Fng to recombinant
FbsA fragments. 5pGST and 6pGST were coated onto
microtiter plates (500 ng/well) and incubated with increasing
amounts of Fng, followed by mouse anti-Fng IgG and HRP-
conjugated rabbit anti-mouse IgG. Values represent the means
of triplicate samples ± S.E. This experiment was performed
three times with similar results. B and C. Surface Plasmon
Resonance analysis of the interaction of 5pGST and 6pGST
with Fng. 5pGST (panel B) and 6pGST (panel C) were
captured on a BIAcore sensor chip coated with goat anti-GST
IgG. Human Fng (2.92 nM to 750 nM) was then flowed over the
chip surface. The data shown are representative of three
individual experiments.
doi: 10.1371/journal.pone.0075266.g003
Figure 4.  Effects of active immunoprotection with the
6pGST FbsA fragment in adult and neonatal mouse
models of GBS sepsis.  A. Immunoprotection in adult mice.
Five-week-old CD1 mice underwent three immunizations with
the 6p FbsA fragment fused to GST (6pGST) or with GST
alone. At 3 weeks after the last immunizations mice were
challenged by the i.p. injection of GBS strain COH1 (5x107
CFUs) and lethality was observed daily. *, p<0.05 relative to
GST-immunized mice by Kaplan-Meier survival plots. Shown
are the cumulative results of two independent experiments. B.
Effect of maternal immunization on survival of experimentally
infected pups. Female CD1 mice (5 wk old) were immunized
three times with the 6p FbsA fragment fused to GST (6pGST)
or with GST alone. Mice were then time-mated and two-day-old
pups were infected s.c. with 250 CFUs of GBS strain 6313. *,
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mediated Fng binding or both. To gain further insights on this,
we took advantage of availability of a panel of mAbs raised
against a synthetic analog of the FbsA repeat motif ( [16], G.P.
and P.S., unpublished results). From this panel, we selected
two IgG1k mAbs, 5H2 and 10H1. Of these, 5H2, but not 10H1,
was capable of completely preventing binding of soluble Fng to
6pGST (Figure S2), as well as GBS adherence to immobilized
Fng (Figure S3). The selected mAbs were next used to prevent
lethality in the neonatal model of GBS disease. As reported in
Figure 5, panels B and C, both 10H1 and the control IgG1k did
not affect of the pups. In contrast, the neutralizing 5H2 mAb
markedly protected neonates against GBS-induced lethality
using challenge doses that killed nearly all of the control pups.
These results indicated that the protective activities conferred
by anti-FbsA antibodies were likely related to their ability to
neutralize Fng binding. To further exclude the possible role of
5H2 in the phagocytic process, 5H2 F(ab’)2 fragments were
prepared and tested for protection in a passive immunization
experiment. As shown in Figure S4, administration of equimolar
amounts of whole 5H2 IgG or 5H2 F(ab’)2 fragments
determined a similar pattern of survival of GBS-inoculated
pups. Overall, these data indicated that the protective effects of
mAb 5H2 against GBS infection were not due to bacterial
opsonization or other Fc-dependent functions, but rather to
neutralization of FbsA-Fng interactions.
Effects of fbsA deletion on GBS virulence
The impact of fbsA deletion on GBS virulence has been
previously studied only in a septic arthritis model in adult mice
[17]. Therefore we next investigated whether FbsA deficiency
affects the outcome of GBS-induced lethal sepsis and whether
such effects differ in neonatal, as compared to adult, disease
models. The latter point was of particular interest, since
neonatal hypersusceptibility to GBS may be linked to a relative
complement deficiency [20] and Fng bound to the surface of
group A streptococci can inhibit complement deposition [21].
Neonatal and adult mice were infected with a previously
described GBS mutant bearing a deletion in the fbsA gene
[11,16] and with the parental wild type 6313 strain. As
expected, much higher doses of the wild type strain were
required to induce lethal infection in adults, compared to two-
day-old pups (2x108 and 250 CFU, respectively, Figure 6).
However, a similar loss of virulence of the ΔfbsA strain, relative
to the parental 6313 strain, was observed in the neonatal and
in the adult models (Figure 6). These data indicated that FbsA
has an important role in the pathogenesis of GBS sepsis and
that the extent to which virulence is affected by the absence of
this protein is similar in adult and neonatal mice.
Discussion
The intrapartum administration of antibiotics to colonized
women has been associated with decreased incidence of GBS
infections during the first week of life in several countries [22].
Despite this, GBS persists as a major public health issue
worldwide and as a frequent cause of disease in neonates, in
adults with predisposing conditions and in the elderly [20].
Since it can potentially prevent GBS-induced disease in all age
Figure 5.  Effects of passive immunization in GBS sepsis
models.  A. Effect of administration of sera from 6pGST- or
GST-immunized adult animals. Two-day-old pups born to
unimmunized mothers were administered with immune sera
(diluted 1:10) via a s.c. route. After 3 h, pups were infected s.c.
with 250 CFUs of GBS strain 6313. *, p<0.05 relative to anti-
GST serum treated-mice by Kaplan-Meier survival plots. B and
C. Effects of passive immunization with anti-FbsA mAbs 5H2
and 10H1 (both IgG1k). Two-day-old pups born to unimmunized
mothers were administered 50 (B) or 10 (C) µg of mAb 5H2,
mAb 10H1 or mouse IgG1 (isotype control) via an s.c. route.
After 3 h, pups were infected s.c. with 250 CFUs of GBS strain
6313. *, p<0.05 relative to IgG1k- or 10H1mAb-treated mice by
Kaplan-Meier survival plots. Each panel summarizes the
results of one independent experiment.
doi: 10.1371/journal.pone.0075266.g005
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groups, including stillbirths, vaccination represents the most
effective and sustainable long-term preventive strategy. Clinical
trials have indicated that immunization with capsular
polysaccharides conjugated with tetanus toxoid is effective in
inducing anti-capsular antibodies capable of enhancing
phagocyte-mediated bacterial killing [20]. Moreover, much
attention has been recently devoted to the identification of
protein antigens of GBS that may be useful, either alone or as
carriers in polysaccharide-protein conjugates, to increase the
efficacy and the strain coverage of anti-GBS vaccines [23,24].
The main finding of the present study is that a Fng-binding
fragment of the GBS protein FbsA has immunoprotective
activity, which is likely mediated by the induction of neutralizing
anti-FbsA antibodies.
Figure 6.  Effects of deletion of the fbsa gene on GBS
virulence in adult and neonatal mouse models of GBS
sepsis.  A. Eight-week-old CD1 mice of either sex were
injected i.p. with 2x108 CFUs of GBS strain 6313 or of its fbsa-
deleted (Δ-fbsa) mutant. Shown are cumulative survival data
from two independent experiments. *, p<0.05 relative to wild-
type by Kaplan-Meier survival plots. B. Two-day-old CD1 pups
were infected s.c. with 250 CFUs of GBS strain 6313 or of its
fbsA-deleted (Δ-fbsA) mutant. *, p<0.05 relative to wild-type by
Kaplan-Meier survival plots. Shown are cumulative survival
data from two independent experiments.
doi: 10.1371/journal.pone.0075266.g006
In several bacterial pathogens, the capability to bind host
Fng has been associated with an increased ability to cause
invasive disease [7]. After screening genomic GBS libraries for
Fng binding, we isolated several sequences of DNA encoding
FbsA fragments. In contrast, sequences of other GBS proteins
that are also known to bind Fng, such as FbsB [12] or Srr1 [14],
were not detected despite the fact that the corresponding
genes were present in the genomes used to construct the
libraries. The reasons for this are unclear, but may be related
to a number of hypothetical factors including a bias against the
expression of certain proteins by our phage libraries or a
relative lack of sensitivity of our immunoscreening assay, which
may preferentially detect high-affinity interactions. It is
interesting to note, in this respect, that the affinity for our FbsA
fragments of Fng, as measured in the present study, is
considerably higher than that reported for whole FbsB [12].
In the present study, we focused on the immunoprotective
activities of an FbsA fragment, designated 6p. Notably, active
maternal immunization with 6p significantly protected pups
from lethal GBS challenge and such protection could be
recapitulated by the administration of sera from 6p-immunized
adult animals to pups born to unimmunized dams. These data
were not apparently in accordance with a previous study where
active immunization with the N-terminal portion of FbsA, or
passive immunization with an anti-FbsA mAb, did not
ameliorate the outcome of septic arthritis in mice. It is likely that
the remarkable difference between the present study and the
previous one is related to the diverse experimental models
used. For example, in our models, GBS was injected. i.p. or
s.c. and replicated in the inoculation site to subsequently
spread into the blood while in the work performed by Jonsson
et al. bacteria were directly injected into the bloodstream and
colonization of distant organs such as the joints and the
kidneys was measured. It is possible that anti-FbsA
immunization is more effective in controlling local replication
and subsequent systemic spreading, than in preventing
hematogenous colonization of target organs.
Moreover, different disease manifestations were used to
evaluate the outcome of infection in the two studies. Here, we
looked at irreversible signs of septic shock and death, which
always occurred within 4 days after inoculation, while in the
Jonsson et al. study outcome was evaluated on the basis of
weight loss and clinical and histological signs of arthritis [17].
Therefore, anti-FbsA immunization may be more effective in
controlling rapidly evolving, life-threatening infections such as
those observed in human neonates, as compared to more
slowly evolving hematogenous arthritis, typically observed in
adults. Finally, it should be noted that different immunogens
(an FbsA fragment encompassing only the Fng-binding region
vs the whole N-terminal FbsA portion) were used by the two
groups. There are several documented instances in which
inoculation with a relatively small fragment of a larger
immunogen, but not the larger immunogen itself, resulted in
protective anti-bacterial immunity [25,26]. Future studies will be
needed to verify whether this phenomenon also applies to
FbsA immunization.
Irrespectively of the mechanism, our data indicate that the 6p
fragment of FbsA may be useful in anti-GBS immunization
FbsA Fragments
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strategies, perhaps in conjunction with polysaccharidic or
proteinaceous antigens, to increase efficacy and/or strain
coverage. Indeed, the fbsA gene is widely present in GBS
strains, having being detected in approximately 80% of human
isolates [13] and in all strains belonging to the hypervirulent
CC17 clone (which largely predominates in neonatal meningitis
isolates [27]), or to the CC23 clone, which is also frequent in
patients with invasive infections [15]. However, due to the
presence of distinct regulatory systems in different strains (13),
FbsA expression may vary considerably. Although
immunization with 6p had a protective effect on the two GBS
strains tested, future studies should be performed to assess
the efficacy of FbsA/6p immunization against a wide variety of
clinical isolates.
The ability to avidly bind Fng and fibrin is a feature of many
Gram-positive extracellular pathogens and may represent a
common, conserved mechanism to penetrate epithelial and
endothelial barriers and/or escape phagocytic killing [21,28].
Streptococcal or staphylococcal mutants lacking Fng-binding
proteins (or the Fng-binding regions of these proteins) are
generally hampered in the ability to produce invasive disease
[7,29]. Despite this, it has been sometimes difficult to prove that
Fng-binding proteins promote virulence by actually binding Fng
in vivo. For example, group A streptococcal mutants lacking the
Fng-binding region of M5 protein are attenuated even in Fng-
deficient mice, suggesting that this region might have functions
other than Fng binding activity [30]. Similarly, although deletion
of fbsA resulted in the attenuation of GBS virulence [11], it is
presently unclear whether this effect is actually linked to the
ability of FbsA to bind Fng in vivo. Such ability may indeed be
crucial for GBS virulence, since administration of neutralizing
anti-FbsA IgG or F(ab’)2 fragments significantly protected pups
from lethal GBS challenge. In sharp contrast, a non-
neutralizing anti-FbsA mAb was totally devoid of protective
activity. These data are in general agreement with a previous
study in which Fab fragments of FbsA-specific antibodies were
as effective as the unfragmented IgG in preventing GBS-
induced lethality in adult mice [18]. All together, we suggest
that the protective activity of anti-FbsA antibodies is related to
the interference with Fng binding, but not to opsonophagocytic
killing, and that induction or administration of neutralizing anti-
FbsA antibodies may be useful at preventing lethal sepsis by
GBS. In conclusion, 6p FbsA fragment may be useful in the
development of anti-GBS vaccines. Moreover, blocking Fng-
FbsA interactions by passive immunization may be a viable
strategy to prevent or treat GBS disease, particularly in the
neonate where comparatively small doses of antibodies would
be needed.
Materials and Methods
Bacterial strains and materials
GBS serotype III COH1 [31] and 6313 [32] strains and
serotype V 2603V/R strain [33] were used in this study. A
previously described 6313 mutant lacking FbsA (ΔfbsA mutant)
[11] was also used in virulence studies. GBS were grown at
37°C in Todd-Hewitt broth containing 1% yeast extract. Human
fibrinogen (Fng) was prepared as previously described [16].
Construction and selection of S. agalactiae phage
displayed libraries
For construction of genomic S. agalactiae λ phage displayed
libraries, we used previously described procedures
[25,34,35,36]. Briefly, 5 µg of streptococcal genomic DNA,
obtained using standard phenol extraction procedures, were
digested using 1 ng of DNaseI (Dnase shotgun cleavage kit,
Novagen, Milan, Italy) at 16°C for 20 min. Fragments with an
average size of approximately 300 bps were then manually cut
from gels, filled in with T4 DNA polymerase (M4211; Promega,
Milan, Italy) and ligated with specific adaptors into vector
λKM4, to be cloned as fusion products with the coat λ phage
protein D [34]. The resulting COH1 and 2603 V/R displayed
libraries contained, respectively, 4 x 106 and 2 x 106
independent recombinant phages, thus providing full coverage
of the genomes of these strains. Selection with Fng was
performed using Fng-coated magnetic beads (Dynabeads
M-280, Invitrogen, Monza, Italy). Coating was performed by
incubating 5 mg of tosyl-activated magnetic beads overnight at
37°C with 50 µg of Fng in 500 µl of borate buffer. Before use,
the beads were blocked by incubation with 1 ml of PBS/milk
(0.05 M phosphate buffered saline supplemented with 5% non-
fat dry milk) for 3h at 20°C, and were reacted for 1h at 20°C
with phages from the COH1 or 2603V/R libraries (1010 PFU in 1
ml). After washing, Escherichia coli LE392 cells, grown to the
exponential phase, were infected with Fng-selected phages
and plated onto LB agar. Plaque immunoscreening was
performed as previously described [34] using Fng (5µg/ml)
followed by rabbit anti-Fng IgG (diluted 1:64,000) (Abcam,
Cambridge, UK) and alkaline phosphatase-conjugated goat
anti-rabbit IgG (diluted 1:2,000, Sigma, Milan, Italy). After
selection, libraries or individual phage clones were analyzed by
a phage enzyme-linked immunoassay (phage ELISA [34]).
Briefly, plates were sensitized with Fng (5 µg/ml) followed by
the addition of a 100 µl suspension containing the indicated
numbers of phage particles. Next, anti-lambda rabbit IgG was
added followed by alkaline phosphatase-conjugated goat anti-
rabbit IgG, as described [25,35]. Phage ELISA inhibition
assays were performed by mixing phages (108 PFU) with
various concentrations of recombinant FbsA fragments (see
below), used as inhibitors.
Production of recombinant FbsA fragments
FbsA fragments expressed on the surface of selected phage
clones were recombinantly produced as previously described
[25,36]. Briefly, inserts from the Fng-binding clones 5p and 6p
(see Results section) were amplified and subcloned into the
pGEX-SN bacterial expression vector [37], to produce pGEX-
SN5p and pGEX-SN6p that allowed the expression of
recombinant proteins as fusions to glutathione S-transferase
(GST). After induction, recombinant fragments were purified
from the cytoplasm of bacterial cells using affinity
chromatography [36]. Recombinant GST, to be used as a
negative control, was produced and purified using the same
method.
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Generation of monoclonal and polyclonal antibodies
Monoclonal antibodies 5H2 and 10H1, both IgG1k, were
raised against an FbsA-derived synthetic peptide as previously
described [16]. 5H2 F(ab’)2 fragments were prepared by
digestion of whole 5H2 IgG with immobilized pepsin, according
to the manufacturer’s instructions (Pierce, Rockford, IL, USA).
Mouse polyclonal antiserum against human Fng was generated
by injecting BALB/c mice intraperitoneally (i.p.) four times at 1-
week intervals with 50 µg of the purified protein. The antigen
was emulsified with an equal volume of complete Freund’s
adjuvant for the first immunization, followed by three injections
in incomplete adjuvant. The mice were bled, and the sera were
tested for reactivity to the purified antigen using ELISA and
Western blot. The use of complete Freund’s adjuvant in the first
immunization was justified by our previous observations that
high-titer sera were more consistently obtained with this
adjuvant, as compared to other less “inflammatory” adjuvants
such as alum. However, care was taken to minimize discomfort
to the animals by injecting a low volume (0.1 ml containing 0.05
mg of mycobacteria) of the oily component of the emulsion and
by using sterile solutions and techniques to prepare it. Under
these conditions, no significant abdominal distension or other
complications at the injection site were observed throughout
the experimental period.
To produce rabbit anti-GBS antibodies, cells of S. agalactiae
R268 were inactivated with 0.8% formol for 48 hours under
stirring conditions. Bacteria were harvested, washed with
phosphate-buffered saline and injected intramuscularly into a
rabbit. The primary immunization consisted of 1 ml of bacteria
(1.5x109) emulsified with an equal volume of complete Freund
adjuvant. Booster doses of streptococci mixed with incomplete
adjuvant were administered by the same route 21, 35, 50 and
65 days after the primary dose. Serum obtained from bled
animal was tested for reactivity to GBS by ELISA. Control
serum was obtained prior to animal inoculation. The antibodies
were purified by affinity chromatography on Protein A/G-
Sepharose columns according to the recommendations of the
manufacturer (GE Healthcare, Milan, Italy). Horseradish
peroxidase (HRP)-conjugated rabbit anti-mouse antibody and
horseradish peroxidase-conjugated goat anti-rabbit IgG were
both from Dako (Glostrup, Denmark). Alkaline phosphatase-
conjugated goat anti-rabbit IgG were purchased from Sigma.
Analysis of Fng binding to recombinant fragments of
FbsA by ELISA
Saturation kinetics of Fng-binding to recombinant FbsA-
fragments were determined by an ELISA assay. Briefly, 5pGST
or 6pGST (500 ng/well) were coated onto microtiter wells
overnight at 4°C in 0.1 M carbonate buffer. The wells were
washed, blocked with 2% BSA for 1 h at 22°C and incubated
with increasing amounts of human Fng. Complex formation
was detected with mouse anti-human Fng IgG (0.3 μg/well),
followed by addition of peroxidase-conjugated rabbit anti-
mouse IgG (1:1000).
Surface plasmon resonance studies
Surface plasmon resonance (SPR) was determined using
the BIAcore X system (GE Healthcare). To measure KD values
of Fng binding to recombinant FbsA fragments (5pGST and
6pGST), goat anti-GST antibody (30 µg/ml) dissolved in 10 mM
sodium acetate buffer, pH 5.0 was immobilized onto a carboxy-
derivatized sensor chip. The 5pGST or 6pGST (500 nM) were
passed over a flow cell, while GST alone was passed in a
reference cell. Human Fng was then flowed over the surface of
both flow cells at concentrations ranging from 2.92 nM to 750
nM at a rate of 20 µl/min. Assay channel data was subtracted
from reference flow cell data to eliminate the effects of non-
specific interactions. The data were analyzed using the BIA
evaluation software version 3.0. A plot of the level of binding
(response units) at equilibrium against analyte concentration
was used to determine KD values.
Inhibitory effect of monoclonal antibodies on GBS
attachment to Fng
Microtiter plates were coated overnight at 4°C with 1 µg
human purified Fng in 100 µl of PBS. The wells were washed
three times with phosphate–buffered-saline and then blocked
with 1% bovine serum albumin for 2 hours. Then, 5x107 cells of
GBS strain 6313, preincubated with the indicated amounts of
anti-FbsA monoclonal antibodies, were added to each well and
the mixtures incubated for 2 hours at 22°C. After extensive
washing of the plates, 1 µg rabbit anti-S. agalactiae IgG was
added to each well, followed by a further incubation for 90
minutes. Subsequently, peroxidase-conjugated goat anti-rabbit
IgG was added, and a color reaction developed after the
addition of o- phenylenediamine. Absorbance at 490 nm was
quantified in a microplate reader (Bio-Rad, Segrate, Milan,
Italy).
Active immunization and challenge of adult mice
To study the protective activity of 6pGST immunization in an
adult mouse sepsis model, CD1 mice (5 wk old), (Charles River
Labs, Calco, Italy) were injected i.p. with 20 µg of 6pGST, or of
GST used as a control, in complete (first injection) or
incomplete (second and third injections) Freund’s adjuvant
emulsions (in a total volume of 0.2 ml) on day 0, 14, and 28.
Three weeks after the last immunization, mice were challenged
i.p. with the COH1 GBS strain (5×107 CFUs) and bled after 18h
from the tail vein to measure blood CFUs by agar plating. Mice
were monitored at least once a day for lethality and signs of
disease for a total of 14 days after challenge. Animals with
signs of irreversible sepsis were humanely euthanized and
their organs were cultured to confirm GBS as the cause of
disease.
Maternal immunization
A previously described murine maternal immunization model
was used [19]. Briefly, female CD1 mice (5 wk old) were
injected i.p. with 20 µg of 6pGST, or GST alone, exactly as
described above. Mice were then time-mated at 2 weeks after
the last immunization. Two-day old pups were infected
subcutaneously (s.c.) with 100 to 250 CFUs of strain 6313
(grown as described above) and observed for disease signs
and lethality for at least 10 days. Deaths never occurred,
however, after 4 days.
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Passive protection model
In passive protection experiments, neonatal mice from non-
immunized mothers were injected s.c. with polyclonal mouse
sera or with monoclonal antibodies before challenge.
Polyclonal mouse sera were obtained by immunizing CD1 mice
(5 wk old) with 6pGST or GST, as described above. After
bleeding mice at 2 weeks after the last injection, sera were
pooled, frozen into 50 µl aliquots and used at a 1:10 dilution in
PBS for injection of neonatal mice (30 µl per pup). Purified
monoclonal antibodies and (Fab’)2 fragments were adjusted to
1 and 0.66 mg/ml concentrations in PBS, respectively, before
the s.c. administration of 30 µl per pup. At 3 h after antibody
administration, pups were challenged with 100 or 250 CFUs of
S. agalactiae strain 6313. Survival was observed for 10 days.
Deaths never occurred, however, after 4 days.
In vivo effects of fbsA deletion
To assess the role played by FbsA in GBS virulence, a
ΔfbsA deletion mutant and the parental 6313 strain were used
to infect adult or neonatal mice. Bacteria were grown to the mid
log phase (OD600 = 0.6), washed and plated for colony counts.
Eight-week old CD1 mice were inoculated i.p. with 2×108
CFUs. Two-day-old pups were challenged with 250 CFUs
administered by the s.c. route.
Ethics statement
All in vivo experiments were conducted at the animal
facilities of the Dipartimento di Scienze Pediatriche,
Ginecologiche, Microbiologiche e Biomediche of the University
of Messina according to the European Union guidelines for the
handling of laboratory animals and were approved by the local
animal experimentation committee (Comitato Etico per la
Sperimentazione Animale, permit 18052010).
Supporting Information
Figure S1.  Blood CFUs in mice immunized with the
6pFbsA fragment. Blood samples were obtained at 18 h after
challenge from the animals used in Figure 4A experiments.
CFUs were counted by plating serial dilutions on blood agar.
For the purpose of statistical analysis, samples in which no
CFU were detected were assigned an arbitrary value
corresponding to one half of the lower detection limit of the
assay. *, p<0.05 relative to GST-immunized mice by one-way
ANOVA and the Student-Keuks-Newman test. Shown are the
cumulative results of two independent experiments.
(TIF)
Figure S2.  Inhibition of Fng binding to 6pGST by the 5H2
mAb. Goat anti-GST was immobilized on the wells of microtiter
plates, followed by incubation with 6pGST (100 nM). Fng (500
nM) was mixed with 1 µg/ml of mAb 5H2, mAb 10H1 or mouse
IgG1 (isotype control) before being added to the wells. After
washing, Fng binding was detected using rabbit anti-Fng
antibodies followed by alkaline phosphatase-conjugated goat
anti-rabbit IgG.
(TIF)
Figure S3.  Inhibition of GBS attachment to surface-coated
Fng by the 5H2 mAb. Cells of S. agalactiae 6313 (5x107) were
preincubated with the indicated amounts of mAbs 5H2 or 10H1,
transferred to Fng-coated wells (1 µg/well) and the mixtures
were incubated for 2 hours. After extensive washes, 1 µg rabbit
anti-GBS IgG was added to the wells, followed by a 90 min
incubation. Adherent bacteria were detected by peroxidase-
conjugated goat anti-rabbit IgG and the plates were developed
with o-phenylenediamine. All the data are expressed as
percentages of control adherence, where bacteria attachment
in the absence of antibody was set to 100% (equivalent to 0%
inhibition). The bars show standard deviations of triplicate
samples. This experiment was performed three times with
similar results.
(TIF)
Figure S4.  Effects of passive immunization with 5H2
F(ab’)2 fragments in a neonatal mouse model of GBS
sepsis. Two-day-old pups born to unimmunized mothers were
administered with equimolar amounts of full length IgG (5H2
IgG or isotype control IgG1k, 30 µg per animal) or with 5H2
F(ab’)2 fragments (20 µg per animal) via s.c. route. After 3 h,
pups were infected s.c. with 250 CFUs of GBS strain 6313. *,
p<0.05 relative to control IgG treated-mice by Kaplan-Meier
survival plots.
(TIF)
Table S1.  Amino acid sequences of inserts of FbsA phage
clones. DNA was amplified from the indicated phage clones
(left column) and sequenced. Deduced amino acid sequences
are listed in the right column.
(TIF)
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